You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 17, November 2, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Breast Cancer
 •Women's Health
 •Women's Health, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Life-threatening Complications From Doxorubicin-Docetaxel Chemotherapy for Breast Cancer

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their study of life-threatening sepsis associated with use of docetaxel plus doxorubicin as adjuvant chemotherapy, Dr Brain and colleagues1 reported 3 cases of febrile neutropenia and severe gastrointestinal toxicity (2 of which were fatal) among 311 patients who were treated with the combination of docetaxel and doxorubicin as postoperative adjuvant therapy for breast cancer. This 0.63% incidence of treatment-related mortality contrasts with our experience, which includes more than 2900 patients treated with docetaxel-doxorubicin combinations in GEICAM 9805,2 BCIRG 001,3 and BCIRG 005. The incidence of treatment-related death from any cause in these trials does not exceed 0.2% (95% confidence interval, 0.19%-0.21%). A similar low rate of treatment-related death with docetaxel-doxorubicin was reported in ECOG 2197.4 The incidence of febrile neutropenia reported by Brain et al (40.8%) is also higher than that reported in these other trials (around 25%) and in a recently published study with exactly . . . [Full Text of this Article]

Miguel Martin, MD
mmartin@geicam.org
Hospital Universitario San Carlos
Madrid, Spain

Charles Vogel, MD
Cancer Research Network
Plantation, Fla

John Crown, MD
St Vincent’s University Hospital
Dublin, Ireland

John Mackey, MD
Cross Cancer Institute
Edmonton, Alberta
for the BCIRG (Breast Cancer International Research Group)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.